Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : to test experimental HIV vaccine in U.S., Europe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2019 | 11:17am EDT
FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the NYSE in New York

(Reuters) - Johnson & Johnson said on Friday it plans to conduct a late-stage study of its investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.

The drugmaker already has a mid-stage HIV vaccine study underway in five southern African countries.

There are currently no vaccines for HIV, a virus that weakens the body's immune system.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
07:39aMARKET SNAPSHOT: Stock Futures Edge Higher As Banks Kick Off Earnings Season
DJ
07:24aJOHNSON & JOHNSON : Raises Outlook, Beats Profit Estimates
DJ
06:56aJOHNSON & JOHNSON : Strong 3Q for Johnson & Johnson and a better outlook
AQ
06:45aJOHNSON & JOHNSON : Reports 2019 Third-Quarter Results
PR
02:48aJ&J's Courtroom Losses Pile Up -- WSJ
DJ
10/14Business events scheduled for Tuesday
AQ
10/14J&J'S JANSSEN : FDA OK's Xarelto in Acutely Ill Medical Patients
DJ
10/14Johnson & Johnson's Legal Challenges Mount
DJ
10/10JOHNSON & JOHNSON : Must Halve Price of Lifesaving TB Drug Bedaquiline
AQ
10/09MARKET SNAPSHOT: Stocks Close Higher, End Two-day Skid As China-U.S. Trade Ta..
DJ
More news
Financials (USD)
Sales 2019 81 582 M
EBIT 2019 25 367 M
Net income 2019 18 056 M
Debt 2019 8 650 M
Yield 2019 2,89%
P/E ratio 2019 19,5x
P/E ratio 2020 17,6x
EV / Sales2019 4,33x
EV / Sales2020 4,05x
Capitalization 345 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 149,05  $
Last Close Price 130,72  $
Spread / Highest target 29,3%
Spread / Average Target 14,0%
Spread / Lowest Target -5,14%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.77%344 992
ROCHE HOLDING AG18.02%248 022
MERCK AND COMPANY10.38%215 942
PFIZER-17.27%199 726
NOVARTIS14.95%199 287
NOVO NORDISK AS17.25%121 422